ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma. by Carvalho, D et al.
ARTICLE
ALK2 inhibitors display beneﬁcial effects
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Diffuse intrinsic pontine glioma (DIPG) is a lethal childhood brainstem tumour, with a quarter
of patients harbouring somatic mutations in ACVR1, encoding the serine/threonine kinase
ALK2. Despite being an amenable drug target, little has been done to-date to systematically
evaluate the role of ACVR1 in DIPG, nor to screen currently available inhibitors in patient-
derived tumour models. Here we show the dependence of DIPG cells on the mutant receptor,
and the preclinical efﬁcacy of two distinct chemotypes of ALK2 inhibitor in vitro and in vivo.
We demonstrate the pyrazolo[1,5-a]pyrimidine LDN-193189 and the pyridine LDN-214117 to
be orally bioavailable and well-tolerated, with good brain penetration. Treatment of immu-
nodeprived mice bearing orthotopic xenografts of H3.3K27M, ACVR1R206H mutant HSJD-
DIPG-007 cells with 25mg/kg LDN-193189 or LDN-214117 for 28 days extended survival
compared with vehicle controls. Development of ALK2 inhibitors with improved potency,
selectivity and advantageous pharmacokinetic properties may play an important role in
therapy for DIPG patients.
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D iffuse intrinsic pontine glioma (DIPG) is an incurableinﬁltrating glioma of the brainstem in children, with amedian overall survival of 9–12 months1–3. The main-
stays of chemotherapy in histologically similar tumours of other
anatomical brain regions are ineffective, in part due to the
absence of factors which predict efﬁcacy, such as MGMT pro-
moter methylation and response to temozolomide4. The
uniqueness of the underlying biology of DIPG is most readily
demonstrated by the high prevalence (>80%) of lysine-to-
methionine substitutions at position 27 (K27M) in genes
encoding histone H3.1 (HIST1H3B, HIST1H3C) and H3.3 var-
iants (H3F3A)5,6. To date, radiotherapy provides the only ther-
apeutic response, although >90% children suffer a relapse and die
from their disease within 2 years1,3,7.
Recent collaborative molecular sequencing initiatives have
deﬁned the genomic landscape of DIPG. We and others identiﬁed
recurrent somatic activating mutations in the gene ACVR1 in ~25%
of DIPG patients8–11. Whilst H3.3 K27Mmutations are also present
in other midline regions such as the thalamus, spine and cerebellum
(diffuse midline glioma with H3K27M mutation in the 2016 WHO
classiﬁcation schema12), ACVR1 mutations are associated with
H3.1K27M substitutions, and appear restricted to DIPG13. In
keeping with the clinicopathological differences between H3.3 and
H3.1 K27M mutant subgroups14, ACVR1 mutations have been
reported at a younger age of diagnosis and with longer overall
survival in children with DIPG8–11. Although apparently not found
in any other human cancer, these variants are found in the germline
of patients with the congenital malformation syndrome ﬁbrodys-
plasia ossiﬁcans progressiva (FOP), in which soft tissue is remo-
delled to bone in response to (often trauma-related) inﬂammation15.
In the brain, activin A—ACVR1 signalling is involved in the process
of myelination16–18, an intriguing association given the putative
oligodendroglial precursor origins of DIPG18–20.
ACVR1 encodes the receptor serine/threonine kinase ALK2,
and in models of FOP, it has recently been reported that the
characteristic mutations confer an aberrant sensitivity to the
ligand activin A, produced as part of the inﬂammatory response,
rather than the canonical BMPs21. This results in increased
pathway activation and cell signalling via a canonical phos-
phorylated SMAD1/5/8-SMAD4 pathway to drive expression of
target genes including ID1/2/3, SNAIL and HEY122. Inhibition of
this response provides the major impetus of preclinical develop-
ment and clinical trials in FOP.
The ﬁrst small molecule inhibitor of ALK2 was dorsomorphin,
identiﬁed through a classical BMP ventralization assay in zebra-
ﬁsh embryos23. The pyrazolo[1,5-a]-pyrimidine scaffold of dor-
somorphin provided the basis of further compounds
demonstrated to target ALK2 and the related BMP receptors
ALK3 and ALK6, without affecting the type I TGF-beta receptor
ALK524. Continued improvements in selectivity have been
reported in a newer series based instead on a pyridine scaffold,
the prototype of which is K0228825.
In the present study, we demonstrate ACVR1 mutations confer
abnormal ligand responsiveness to activin A in DIPG cells, with
spatiotemporal expression of activin A in neurodevelopment
correlating with tumour origins. Screening mutant and wild-type
DIPG cultures with a range of pyrazolo[1,5-a]pyrimidine- and
pyridine-based ALK2 inhibitors demonstrated differential effects
on cell viability, recapitulating genetic knockdown with shRNA,
and prolongation of survival in orthotopic patient-derived
xenograft models of DIPG.
Results
Clinical and molecular correlates of ACVR1 mutant DIPGs. To
assess the differences between distinct somatic variants, we
re-examined data from a genomics meta-analysis comprising 212
DIPG cases for which ACVR1 status was available14. We identi-
ﬁed 50/212 (23.6%) cases with ACVR1 mutation, and found no
differences in age at diagnosis between R206H (n= 10, median=
5.35 years), R258G (n= 7, median= 5.2 years), G328E/V/W
(n= 28, median= 5.5 years) and G356D (n= 5, 4.8 years) var-
iants (p= 0.6957, ANOVA), though together, mutant cases were
signiﬁcantly younger than ACVR1 wild-type DIPG (5.25 vs 7.0
years, p < 0.0001, t-test) (Fig. 1a). The presence of any ACVR1
mutation conferred a longer overall survival (p= 0.00291, log-
rank test), however this beneﬁt was largely restricted to amino
acid substitutions at the G328 residue (median survival=
16.0 months; p= 0.000646, log-rank test), with other mutations
showing no signiﬁcant differences in clinical outcome compared
with ACVR1 wild-type patients (wild-type median survival=
10.0 months; R206H= 13.0 months; R258G= 13.1 months;
G356D= 14.3 months) (Fig. 1b). Of eight long-term survivors
(>24.0 months), ﬁve were ACVR1 mutant (62.5%), all of which
were G328E/V/W; ranking DIPG patients by their overall survi-
val, 10/21 (47.6%) of the top 10% survivors (>19.0 months) were
ACVR1 mutant, all but one G328E/V/W.
Gene expression data were available across three independent
platforms for 66 patients (Supplementary Fig. 1a), with an
integrated analysis identifying 244 differentially expressed genes
between ACVR1 mutant and wild-type DIPGs (adjusted p < 0.05,
Mann–Whitney U test) (Supplementary Table 1). ACVR1
mutation was signiﬁcantly associated with upregulation of known
BMP/TGFβ target genes such as ID1 (p= 0.0261) and ID2 (p=
0.0101), as well as other regulators (EMILIN1, p= 0.00000218)
and antagonists (GREM1, p= 0.00187), in addition to genes
associated with neurogenesis (WIF1, p= 0.0000556), neuronal
migration (RELN, p= 0.0292), differentiation (HOXD8, p=
0.000132) and pluripotency (LIN28B, p= 0.000714) (Fig. 1c).
By gene set enrichment analysis, there was co-ordinated
regulation of expression signatures associated with signalling
through HIF1, TGFβ, WNT, STAT3 and TP53 pathways
(Supplementary Fig. 1b).
There was an expected strong association of ACVR1 mutation
with H3.1K27M (36/50 vs 8/50 H3.3 K27M and 6/50 H3 wild-
type; p < 0.0001, Fisher's exact test), however, the distribution of
histone mutations differed with distinct ACVR1 variants. Notably,
R206H mutant tumours contained equal proportions of H3.3 and
H3.1K27M (Fig. 1d). DIPGs with more extensive genome or
exome sequencing data (n= 154) allowed us to investigate
additional co-segregating mutations, and identiﬁed a signiﬁcant
enrichment of PI3-kinase pathway alterations (PIK3CA, PIK3R1
and PTEN) in ACVR1 mutant compared with wild-type tumours
(22/40, 55% vs 18/114, 15.8%; p < 0.0001), whilst conversely the
TP53 pathway was targeted by mutations in TP53 and PPM1D
signiﬁcantly more commonly in ACVR1 wild-type cases (13/40,
32.5% vs 87/114, 76.3%; p < 0.0001, Fisher’s exact test) (Fig. 1e).
Taking the ACVR1 mutations separately, tumours with R258G
trended towards fewer copy number aberrations (p= 0.0658,
t-test), whilst R206H had signiﬁcantly fewer somatic mutations
(0.0257, t-test) (Supplementary Fig. 1c). There was enrichment
for PIK3CA mutations in R258G tumours, and PIK3R1 in G356D
(log2 odds ratios >2.5), however this failed to reach statistical
signiﬁcance. Screening all somatic mutations highlighted pre-
viously unreported co-segregation of ACVR1 G328E/V/W with
variants in the cyclin-dependent kinase inhibitor CDKN2C (p=
0.0113, Fisher's exact test) and the lysine demethylase KDM6B
(p= 0.0238, Fisher's exact test) (Supplementary Fig. 1d). Gene
expression differences between the various ACVR1 mutations
revealed an upregulation of genes involved in oligodendrocyte
differentiation in G328E/V/W mutant tumours compared to
R206H and G356D, including MOG (myelin oligodendrocyte
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glycoprotein), MAG (myelin-associated glycoprotein), MBP
(myelin basic protein 1) and MOBP (myelin-associated oligoden-
drocyte basic protein) (Supplementary Fig. 1e, f).
Signalling responsiveness and dependencies in ACVR1 mutant
DIPG cells. Mapping gene expression of ACVR1 and INHBA
(activin A) to publically available databases of neurodevelopment
reveals a marked peak of activin A expression in the mid-foetal
period at approximately 19 weeks post-conception, particularly in
the neocortex and striatum, coinciding with that of a K27M gene
expression signature thought to reﬂect the cellular origins of
DIPG26,27. This is in contrast to BMP4/6, which are substantially
reduced at the same time after peaking considerably earlier in
development (Fig. 2a) (Supplementary Fig. 2a). Notably, a similar
pattern of differential expression for Acvr1, Inhba and Inhbb was
noted in the mouse pons/medulla compared to Bmp4 and Bmp6
(Supplementary Fig. 2b). Although employing an artiﬁcial exo-
genous source, using in vitro patient-derived DIPG models10, we
observe a profound increase in phospho-SMAD1/5/8 in ACVR1
mutant cells relative to wild-type only after activin A, rather than
BMP4, stimulation in starved conditions, although the differential
effects downstream on ID1 are similar with both ligands (Fig. 2b)
(Supplementary Fig. 3). Knockdown of ACVR1 by shRNA in
H3.3 K27M, ACVR1 R206H HSJD-DIPG-007 cells caused a
dramatic reduction in cell viability after 4, and especially, 11 days,
demonstrating the dependence of these cells on signalling
through the receptor (Fig. 2c). Knockdown of ACVR1 also
resulted in signiﬁcant cell death, with increased apoptosis seen by
FACS (29.3% shACVR1_5 vs 13.1% shCTRL cells at 7 days)
(Fig. 2d).
Sensitivity of DIPG cells to ALK2 inhibitors. With ACVR1
representing a potential drug target in DIPG, we next explored a
range of pharmacological inhibitors of the protein product of the
gene, ALK2, in a panel of ACVR1 mutant and wild-type cells. We
tested 11 compounds of distinct chemical series (Supplementary
Fig. 4), including those based on the pyrazolo[1,5-a]pyrimidine
scaffold (dorsomorphin, DMH1, LDN-193189, LDN-212854)
(Fig. 3a), a series of pyridine compounds (K02288, LDN-214117,
LDN-213844, LDN-213819) (Fig. 3b), as well as selected
approved or clinically-investigated drugs with reported anti-
ALK2 activity, including perhexiline maleate, momelotinib, and
saracatinib (Supplementary Fig. 5). Whilst DIPG cells were lar-
gely insensitive to DMH1 and saracatinib, we observed GI50
values in the 1–10 µM range for the remaining compounds, with
some selectivity against the R206H mutant HSJD-DIPG-007 cells,
particularly for dorsomorphin (p= 0.0064) and the K02288
derivatives LDN-213844 (p= 0.0221) and LDN-213819 (p=
0.0004, all t-test) (Table 1). K02288 itself was most potent in the
R258G mutant HSJD-DIPG-018 cells, which were conversely less
sensitive than other mutants to the pyrazolo[1,5-a]pyrimidine
compounds.
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Fig. 1 Somatic ACVR1mutations in DIPG. a Boxplot showing age at diagnosis of DIPG cases, separated by ACVR1 variant (n= 206). The lower and upper limits
of the boxes represent the ﬁrst and third quartiles, and the whiskers 1.5x the interquartile range. *** adjusted p < 0.0001 for all pairwise comparisons, t-test.
b Kaplan–Meier plot of overall survival of cases separated by ACVR1 variant, p-value calculated by the log-rank test (n= 171). c Boxplots representing gene
expression differences between ACVR1 mutant (purple) vs wild-type cases (grey) in an integrated gene expression dataset (n= 66). d Stacked barplot of
distribution of H3 K27M mutations separated by ACVR1 variants. Dark green=H3.1 K27M, light green=H3.3 K27M, grey=wild-type (n= 212). e Oncoprint
representation of an integrated annotation of somatic mutations and DNA copy number changes for selected genes in DIPG (n= 154). Samples are arranged
in columns with genes labelled along rows. Clinicopathological and molecular annotations are provided as bars according to the included key
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The most potent compound was LDN-193189, with GI50
values in the range 0.70–3.16 µM, although little selectivity was
observed between ACVR1 mutant and wild-type cells. By
contrast, the most selective compound was the pyridine LDN-
214117, with GI50 values of 1.57 µM for R206H HSJD-DIPG-007
cells, 5.83–6.23 µM for G328V SU-DIPG-IV, and ACVR1 wild-
type (but high phospho-SMAD1/5/8 expressing) SU-DIPG-VI
cells, and 8.27 µM for ACVR1 wild-type QCTB-R059 cells (p <
0.0001, t-test) (Table 1). Both compounds were seen to inhibit
signalling through phospho-SMAD1/5/8 and the downstream
effector ID1, with the ﬁrst effects seen at 4 h with 0.1 µM, but
more profound consequences seen at 1.0 µM (Fig. 4a, b)
(Supplementary Fig. 3). Induction of apoptosis evidenced by an
increase in cleaved PARP was seen in ACVR1 mutant, but not
wild-type cells.
Such effects were not transient, with wash-out experiments for
both compounds showing a persistent inhibition of downstream
signalling 24 h post-treatment (Supplementary Fig. 6a, b). In the
presence of ligands, there was no difference in GI50 values for
LDN-193189 (Supplementary Fig. 6c), however, addition of
Activin-A conferred enhanced sensitivity of R206H HSJD-DIPG-
007 cells to LDN-214117 (Supplementary Fig. 6d). In order to
assess whether treatment of DIPG with these compounds would
afford a therapeutic window, we also assessed their effects on
normal human astrocytes derived from the brainstem (NHA-BS).
For both LDN-193189 (Supplementary Fig. 6e) and LDN-214177
(Supplementary Fig. 6f), there was a marked lack of sensitivity in
the NHA-BS cells, with greater than 10-fold difference in effect
on cell viability compared to the DIPG cultures.
Pharmacokinetics and pharmacodynamics of ALK2 inhibitors.
We next investigated which of the tested compounds possessed
the desired biopharmaceutical proﬁles in terms of CNS penetra-
tion and in vivo effects on downstream signalling. Plasma drug
exposure (area under the curve, AUC) was assessed for six
compounds after oral and intravenous treatment, and bioavail-
ability (F) was calculated. Those with the highest F were
LDN-193189 (0.94), and to a lesser extent, LDN-214117 (0.75)
(Supplementary Fig. 7). Both LDN-193189 and LDN-214117
were found to be well-tolerated in mice at 35 and 25mg/kg,
respectively, despite an initial weight loss with LDN-193189
(Fig. 5a, e). The concentrations of both compounds in the blood
persisted over 8 h post oral administration (Fig. 5b, f), whilst
importantly, brain levels were either even higher (LDN-193189
brain:plasma ratio= 1.34, 2 h post-dose, day 14) (Fig. 5c) or only
slightly reduced compared with plasma (LDN-214117 brain:
plasma ratio= 0.80, 2 h post-dose, day 14) (Fig. 5g). In both
cases, the concentrations in mouse brain (3.37 and 10.94 µM)
were considerably higher than the in vitro GI50 values observed
(0.70 and 1.57 µM). Treatment at these concentrations also lead
to a substantial reduction in pharmacodynamic biomarkers in
HSJD-DIPG-007 xenograft tumours, showing a near-ablation of
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Fig. 2 ACVR1 in development and DIPG models. a Expression of ACVR1 (ALK2) and INHBA (activin A) in anatomical structures of the developing and adult
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medial prefrontal cortex; OFC, orbital prefrontal cortex. b Pathway activation by western blot of DIPG patient-derived cell cultures in response to growth
factor starvation, and treatment with either BMP4 or Activin A. GAPDH is the loading control. c shRNA knockdown of ACVR1 in HSJD-DIPG-007 cells.
(left) qRT-PCR analysis of ACVR1 expression in response to gene-speciﬁc constructs and shCTRL. (right) Effect of ACVR1 knockdown on cell number
in vitro over 11 days. d Flow cytometry analysis by annexinV/propidium iodide staining of cell death in HSJD-DIPG-007 cells treated with shACVR1
constructs 2 and 5 and shCTRL. Early (bottom right) and late (top right) apoptotic cells are quantiﬁed
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phospho-SMAD1/5/8 and ID1 with LDN-193189, and to a lesser
extent with LDN-214117 (Fig. 5d, h; Supplementary Fig. 3).
In vivo efﬁcacy of targeting ALK2. Having identiﬁed two can-
didate compounds of distinct chemotypes with in vitro efﬁcacy
linked to effects on DIPG signalling, and brain penetration at
doses sufﬁcient to elicit a similar response in vivo, we next
investigated their efﬁcacy in orthotopic patient-derived xeno-
grafts. We treated established ACVR1 mutant HSJD-DIPG-007
and H3/ACVR1 wild-type (Supplementary Fig. 8a–c) brainstem
xenografts at four and three weeks post-implantation, respec-
tively, with either 25 mg/kg LDN-193189 or LDN-214177 for
28 days. No differences in survival were observed in wild-type
control HSJD-GBM-001 tumours for either compound. By
contrast, for both LDN-193189 and LDN-214177 we observed a
signiﬁcant prolongation of survival in ACVR1 R206H-mutant
HSJD-DIPG-007-bearing animals, amounting to a median beneﬁt
of 15 days in both cases (82 vs 67 days, p= 0.0002, LDN-193189;
and 75 vs 61 days, p= 0.003, LDN-214117, log-rank test) (Fig. 6a,
b, e, f). After 28 days, there was a decrease in cellularity of the
treated ACVR1 mutant tumours compared with controls, as
assessed by counting of positive cells by immunohistochemical
staining using anti-human nuclear antigen (p= 0.0079, LDN-
214117, t-test) (Fig. 6c, d, g, h), though differences in proliferation
(Ki67) (Supplementary Fig. 8d–g), and vascularisation (CD31)
(Supplementary Fig. 8h–k) were not signiﬁcant.
In summary, ACVR1 mutations elicit a dependency of
downstream signalling in DIPG cells than can be inhibited by
single agents of multiple chemotypes of inhibitor compounds
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Fig. 3 Screening of ALK2 inhibitors in vitro. Concentration-response curves for eight ALK2 inhibitors tested against three ACVR1 mutant cell cultures
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Table 1 Screening of ALK2 inhibitors
HSJD-DIPG-007 SU-DIPG-IV HSJD-DIPG-018 SU-DIPG-VI QCTB-R059
Histone H3 H3F3A K27M HIST1H3B K27M HIST1H3B K27M H3F3A K27M H3F3A K27M
ACVR1 ACVR1 R206H ACVR1 G328V ACVR1 R258G ACVR1 wild-type ACVR1 wild-type
Dorsomorphin 1.85 ± 0.15 µM 6.21 ± 0.84 µM 8.70 ± 0.71 µM 5.01 ± 0.75 µM 10.36 ± 1.44 µM
DMH >20 µM >20 µM >20 µM >20 µM >20 µM
LDN-193189 0.70 ± 0.09 µM 0.80 ± 0.02 µM 3.16 ± 0.23 µM 1.10 ± 0.20 µM 0.89 ± 0.01 µM
LDN-212854 1.25 ± 0.05 µM 1.30 ± 0.20 µM 3.22 ± 0.22 µM 1.70 ± 0.20 µM 1.70 ± 0.00 µM
K02288 9.10 ± 0.26 µM >20 µM 14.34 ± 1.13 µM >20 µM >20 µM
LDN-214117 1.57 ± 0.03 µM 6.23 ± 0.30 µM 16.38 ± 0.79 µM 5.83 ± 0.18 µM 8.27 ± 0.33 µM
LDN-213844 3.67 ± 0.66 µM 12.79 ± 2.65 µM 15.44 ± 0.94 µM 12.70 ± 2.17 µM >20 µM
LDN-213819 3.27 ± 0.15 µM 8.03 ± 0.31 µM 11.18 ± 0.61 µM 9.87 ± 0.94 µM 10.99 ± 1.63 µM
Perhexiline 4.07 ± 1.31 µM 4.70 ± 1.01 µM 6.11 ± 0.12 µM 4.90 ± 1.08 µM 5.33 ± 1.07 µM
Saracatinib 17.76 ± 0.56 µM >20 µM >20 µM >20 µM >20 µM
Momelotinib 7.32 ± 0.99 µM 14.23 ± 0.89 µM 9.50 ± 0.38 µM 10.42 ± 1.12 µM 15.94 ± 1.44 µM
Table of GI50 values for 11 compounds screened against four patient-derived DIPG cell cultures, with cell viability as the readout. Mean and standard error of the mean from at least n= 3 independent
experiments are provided
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which penetrate orthotopic tumours at concentrations that
produce cell death and survival beneﬁt in orthotopic mouse
models as single agents at well-tolerated dosages.
Discussion
The discovery of somatic ACVR1 mutations in DIPG identical to
those found in the germline of FOP patients has not only
highlighted unexpected links between neurodevelopment and
chondrogenesis, but also allowed for the fast-tracked evaluation
of speciﬁc ALK2 inhibitors developed for the control of het-
erotopic ossiﬁcation in the context of childhood brain
tumours24. Inhibition of ALK2, via pharmacologic or genetic
means, led to inhibition of proliferation and induction of
apoptosis, as well as a selective reduction in cell viability in
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Fig. 5 In vivo pharmacokinetics/pharmacodynamics of LDN-193189 (top) and LDN-214117 (bottom). a, e Tolerability in NOD.SCID mice exposed to daily oral
treatment with inhibitor over 14 days, as assessed by body weight relative to day 0. Mean and standard deviation of 3 mice per group are plotted. b, f Blood
levels of compounds up to 8 h post-exposure to a single oral dose of drug at day 14. Mean and standard deviation of 3 mice per group are plotted. c, g Barplot
of compound concentrations in blood (red), plasma (yellow) and brain tissue (blue) 2 h post-exposure to a single oral dose of drug at day 14. Mean and
standard deviation of 3 mice per group are plotted. d, hWestern blot analysis of downstream pathway inhibition in three orthotopic HSJD-DIPG-007 tumours,
after mice were treated with daily oral administration of compound, at the end of 28 days, compared with untreated controls. α-tubulin is the loading control
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patient-derived in vitro tumour models, and enhanced survival
of mice bearing orthotopic ACVR1-mutant patient-derived
DIPG xenografts in vivo.
A major challenge in the context of DIPG (unlike FOP) is the
necessity for agents to penetrate the tumour behind what may be a
particularly restrictive blood-brain barrier within the brainstem.
Short-cutting drug development by using the reported off-target
effects on ALK2 of drugs licensed for alternate targets and dif-
ferent indications holds promise given the urgency of the unmet
clinical need, but appeared unwarranted for the compounds tested
here (perhexiline maleate28, saracatinib29 and momelotinib30).
In our mouse models, derivatives of the earliest pyrazolo[1,5-a]
pyrimidine- and pyridine-based compounds (LDN-19318931 and
LDN-21411732, respectively) were found to be present within the
brain at concentrations sufﬁcient to ablate signalling via phospho-
SMAD1/5/8 and ID1, biomarkers indicative of pathway inhibi-
tion and efﬁcacy. With their good potency and selectivity,
LDN-193189 and LDN-214117 are promising lead compounds.
They have attractive physicochemical properties consistent with
their CNS penetration and good pharmacokinetics due to low
clearance and moderate volume of distribution. Notably, the
distinct inhibitors were found to have differences in speciﬁcity for
ACVR1 mutant vs wild-type cultures, and determining such
speciﬁcity proﬁles will be an important part of future drug
development. Furthermore, the distinct ACVR1 mutations found
in DIPG may themselves respond differently, with R206H more
sensitive across a range of compounds, whilst the R258G mutant
cells were largely insensitive to the pyrazolo[1,5-a]pyrimidines,
though responded well to the pyridine-based compounds. There
was also a clear therapeutic window demonstrated in respect of
the lack of sensitivity in vitro of normal human astrocytes derived
from the brainstem. Future development of inhibitors capable of
producing effects across the whole spectrum of variants observed
in DIPG patients will be critical to maximise patient beneﬁt.
In FOP, ACVR1 mutations confer aberrant responsiveness to
the ligand activin A, an effect we demonstrate in DIPG, albeit
using the addition of exogenous ligand in vitro. Of more clinical
relevance is the observation that activin A expression also appears
to peak at the predicted temperospatial origins of DIPG during
neurodevelopment, suggestive of a direct mechanistic link to
tumour development. Activin-A and Acvr1 were also substantially
elevated in the mouse pons/medulla compared to Bmp4 and
Bmp6, implying a feasible mechanism of receptor activation in
our in vivo orthotopic xenograft experiments. Enhanced signal-
ling by BMPs in the context of adult glioma is associated with a
pro-differentiation programme33. ACVR1 / H3.1 K27M mutant
tumours appear to have a more astrocytic rather than oligoden-
droglial gene expression signature and morphological appear-
ance34, although in terms of putative developmental origin it
should be noted that activin A—ACVR1 signalling is associated
with oligodendrocyte differentiation and myelination16,17, a
developmental process actively occurring at the age and location
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Fig. 6 In vivo efﬁcacy of LDN-193189 and LDN-214117 in orthotopic DIPG xenograft models. a Survival curves for mice (n= 7–10 per group) bearing HSJD-
GBM-001 orthotopic xenografts, treated with LDN-193189, compared with vehicle-treated controls. b Survival curves for mice (n= 7–10 per group) bearing
HSJD-DIPG-007 orthotopic xenografts, treated with LDN-193189, compared with vehicle-treated controls. c Immunohistochemistry of control and treated
tumours for LDN-193189, in both models, for anti-human nuclear antigen (HNA). Scale bar= 1000 µM. d Magniﬁed view of HNA staining (scale bar=
50 µM), and barplot quantifying cellularity by HNA-positive cells as a percentage of control. e Survival curves for mice (n= 7–10 per group) bearing HSJD-
GBM-001 orthotopic xenografts, treated with LDN-214117, compared with vehicle-treated controls. f Survival curves for mice (n= 7–10 per group) bearing
HSJD-DIPG-007 orthotopic xenografts, treated with LDN-214117, compared with vehicle-treated controls. g Immunohistochemistry of control and treated
tumours for LDN-214117, in both models, for anti-human nuclear antigen (HNA). Scale bar= 1000 µM. h Magniﬁed view of HNA staining (scale bar=
50 µM), and barplot quantifying cellularity by HNA-positive cells as a percentage of control. Mean and standard deviation plotted. **p < 0.01, t-test
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at which DIPG arises. Notably, genes associated with oligoden-
drocyte differentiation were elevated in G328E/V/W mutant
tumours compared to R206H/G356D. Although Activin A con-
fers enhanced signalling via the same phospho-SMAD1/5/
8-SMAD4 axis as BMPs, it remains possible that various non-
canonical pathways may also be activated within this speciﬁc
context. Gene expression signatures point towards a delicate
balance associated with hypoxia34 and stem cell niche main-
tenance that remain unexplored.
Notably, not all ACVR1 mutations appear to confer a better
prognosis. The R206H mutation, which in the germline accounts
for >95% of classical FOP patients35, does not have the striking
predilection for H3.1 K27M mutations seen with the other var-
iants, and being found in roughly equivalent numbers of H3.3
K27M tumours likely accounts for the extremely poor survival of
these patients. That LDN-193189 and LDN-214117 were able to
produce a survival beneﬁt in vivo in a particularly aggressive H3.3
H27M/ACVR1 R206H model of DIPG provides hope that such
interventions may be more widely applicable to other genotypes.
Although statistically signiﬁcant, the effect seen with these
compounds was relatively modest, producing no cures in our
mouse models, similar to other single agent intervention studies
in DIPG36–39. Consequently, it is unclear how much beneﬁt
would be translated to the clinical setting of ALK2 inhibitors as
single agents. Precisely how dependent DIPG cells are on the cell
signalling conferred by ACVR1 mutations at the time of pre-
sentation is not known, nor are the possible interactions of these
inhibitors with the radiotherapy that all children with DIPG are
currently given. Identiﬁcation of co-segregation of ACVR1
mutation and dysregulation in the PI3K pathway potentially
points the way towards combinatorial approaches which may be
tested in this subgroup of tumours. The Akt inhibitor perifosine
was one of the earliest compounds evaluated in DIPG models40
and translated to the clinic41; sensitivity to the mTOR inhibitor
TAK228 (MLN0128)42 and dual PI3K-mTOR inhibitor
BKM12036 have also recently been reported and an ongoing
stratiﬁed medicine trial in DIPG patients includes everolimus as
one of three investigational arms (NCT02233049). The genetic
dependence and preclinical efﬁcacy demonstrated here with
inhibitors of ALK2 raises the prospect of another class of com-
pounds entering the clinical trials toolkit for children with this
devastating disease.
Methods
Bioinformatic analysis. Curated gene-level copy number, expression and muta-
tion data from DIPG patients were obtained from a recent meta-analysis of pub-
lished and unpublished data14 and is available within the paediatric-speciﬁc
implementation of the cBioPortal genomic data visualisation portal (pedcbioportal.
org). Gene expression data from Agilent WG2.5, Affymetrix U133Plus2.0 or RNA
sequencing were platform-centred, and log-transformed expression measures were
combined and further normalised using pairwise loess normalisation. Gene Set
Enrichment Analysis (software.broadinstitute.org/gsea) was performed using the
GSEA java application based upon pairwise comparisons of the major subgroups in
the merged dataset. Differential expression analysis was based on a Mann–Whitney
U test of centred expression values between cases. Spatiotemporal gene expression
data from developing and adult brain samples were obtained from the Human
Brain Transcriptome project (hbatlas.org)43.
Cell culture. All patient-derived material for cell culture was collected under IRB
approval from Children’s Health Queensland Hospital. Patient-derived cultures
HSJD-DIPG-007 (H3F3A K27M, ACVR1 R206H), HSJD-DIPG-018 (HIST1H3B
K27M, ACVR1 R258G), SU-DIPG-IV (HIST1H3B K27M, ACVR1 G328V), SU-
DIPG-VI, QCTB-R059 (both H3F3A K27M, ACVR1 wild-type), and HSJD-GBM-
001 (H3/ACVR1 wild-type) were grown in stem cell media consisting of Dulbecco’s
Modiﬁed Eagles Medium: Nutrient Mixture F12 (DMEM/F12), Neurobasal-A
Medium, HEPES Buffer Solution 1M, sodium pyruvate solution 100 nM, non-
essential amino acids solution 10 mM, Glutamax-I Supplement and Antibiotic-
Antimycotic solution (all Thermo Fisher, Loughborough, UK). The media was
supplemented with B-27 Supplement Minus Vitamin A, (Thermo Fisher), 20 ng/ml
Human-EGF, 20 ng/ml Human-FGF-basic-154, 20 ng/ml Human-PDGF-AA,
20 ng/ml Human-PDGF-BB (all Shenandoah Biotech, Warwick, PA, USA) and
2 µg/ml Heparin Solution (0.2%, Stem Cell Technologies, Cambridge, UK). Normal
Human astrocytes from the brainstem (NHA-BS) (Science Cell, #1840) were cul-
tured according to manufacturer instructions. Brieﬂy, cells were grown in complete
astrocyte medium (Science Cell, #1840) using poly-lysine (Science Cell, #0413)
coated ﬂasks. Cell authenticity was veriﬁed using short tandem repeat (STR) DNA
ﬁngerprinting, and cells are available upon request.
Western blot analysis. For growth factor starvation, cells were washed twice with
PBS and then incubated for 1 h in stem cell medium without growth factors. Stem
cell medium supplemented with BMP4 (10 ng/ml, Peprotech, London UK) or
activin A (10 ng/ml, Thermo Fisher) was then added for 1 h and protein was
collected. For treatment with LDN-193189 and LDN-214117, cells were incubated
in complete media with vehicle or increasing concentrations of drug (0.1, 1, 10 µM)
and protein was collected at 4 and 8 h post-treatment. For washout experiments,
cells were incubated with 1 µM of LDN-193189 or LDN-214117 and either left in
the culture media or washed out by media replacement for 2–24 h. Mouse brain
samples were manually homogenised in protein cell lysis buffer. Samples were lysed
by using lysis buffer (CST) containing phosphatase inhibitor cocktail (Sigma,
Poole, UK) and protease inhibitor cocktail (Roche Diagnostics, Burgess Hill, UK).
Following quantiﬁcation using Pierce BCA Protein Assay Kit (Thermo Fisher),
equal amounts of cell extracts were loaded for Western blot analysis. Membranes
were incubated with primary antibody (1:1000) overnight at 4 °C, and horseradish
peroxidase secondary antibody (Amersham Bioscience, Amersham, UK) for 1 h at
room temperature. Signal was detected with ECL Prime western blotting detection
agent (Amersham Biosciences), visualised using Hyperﬁlm ECL (Amersham
Biosciences) and analysed using an X-ray ﬁlm processor in accordance with
standard protocols. Primary antibodies used were phospho-SMAD1/5/8
(CST#13820), phospho-SMAD2 (CST#3101), SMAD2 (CST#5339), PARP
(CST#9542), α-tubulin (CST#2125), and GAPDH (CST#2118), all Cell Signalling
(Danvers, MA, USA), and SMAD1/5/8 (SC#6031), SMAD4 (SC#7966), and ID1
(SC#488), all Santa Cruz Biotechnology (Dallas, TX, USA).
ACVR1 shRNA knockdown, qRT-PCR and apoptosis analysis. Lentiviral parti-
cles for shRNA knockdown of ACVR1 were produced by co-transfecting the
packaging vectors (pMD2.G, pMDLg/RRE and pRSV-Rev), and one individual
shRNA expression vector into 293T cells. ACVR1 shRNA vectors (Sigma) used
were as follows: TRCN0000382239 (TRC2, shACVR1-1), TRCN0000315051
(TRC2, shACVR1-2), TRCN0000315051 (TRC2, shACVR1-3), TRCN0000000443
(TRC1, shACVR1-4) and TRCN0000000445 (TRC1, shACVR1-5) or the scram-
bled control shRNA vector (SHC002, shCTRL). Viral particles were concentrated
using Lenti-x concentrator (Clontech, Mountain View, CA, USA) and resuspended
in stem cell media. HSJD-DIPG-007 cells were plated onto laminin-coated plates
and 24 h later transduced with either ACVR1 or control shRNA lentiviral particles
at a multiplicity of infection of 1 in the presence of polybrene (4 µg/ml). Viral
medium was removed 24 h later and cells were selected with puromycin (5 µg/ml).
On day 4 post-selection, cells were collected and RNA extracted for quantitation of
ACVR1 expression by qRT-PCR. RNA was reverse-transcribed using Superscript II
Reverse Transcriptase (Thermo Fisher), followed by quantitative PCR using the
Maxima SYBR Green/ROX qPCR (Thermo Fisher) on an Applied Biosystems
7900HT instrument. Reactions contained 0.5 μg RNA and individual measure-
ments of human ACVR1 and human GAPDH endogenous control were measured
in triplicate. On days 4 and 11 cells were counted using a Vi-CELL XR (Beckman
Coulter, High Wycombe, UK). Cellular apoptosis was measured using AnnexinV-
APC Apoptosis Kit (BD Bioscience, Oxford, UK) on day 7 post-selection. Propi-
dium Iodide (PI) was used as a vital dye. Cells were subjected to Annexin V/PI
FACS analysis to assess the proportion of cells undergoing apoptosis. For FACS
analyses, the stained cells were analyzed using BD machine (BD Biosciences).
Compound efﬁcacy assays. Cells were plated at a density of 2000–4000 cells/well
on laminin-coated 96-well plates in a minimum of triplicates. After three days of
incubation, compound was added to each well in concentrations from 0.07–20 µM
and incubated at 37 °C, in 5% CO2, 95% humidity for eight days (192 h). For
Activin A / BMP4 studies, cells were supplemented with media containing BMP4
(10 ng/ml, Peprotech, London UK) or Activin A (10 ng/ml, Thermo Fisher) 24 h
prior to adding the drug. Drug was added in media supplemented with Activin A
and BMP4 in concentrations from 0.07 to 20 µM and incubated at 37 °C, 5% CO2,
95% humidity for eight days (192 h). Dorsomorphin, DMH1, perhexiline maleate,
LDN-193189, LDN-212854 and LDN-214117 were purchased from Sigma-Aldrich;
saracatinib and momelotinib were purchased from Selleckchem (Houston, TX,
USA); K02288 was purchased from BioFocus (Saffron Walden, UK); LDN-213844
(K03841b), LDN-212838 (K03449c) and K05907 were synthesised at the Structural
Genomics Consortium, Oxford (see Supplementary Methods for chemical struc-
tures and synthesis). LDN-213819 was a kind gift from Paul Yu and Greg Cuny
(Harvard University). Cell viability was assessed by the CellTiter-Glo luminescent
cell viability assay (Promega, Madison, WI, USA) and GI50 values were calculated
using GraphPad Prism version 6 as the concentration of compound required to
reduce cell viability by 50%.
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Statement of compliance with ethical regulations guiding proper use of
laboratory animals. All experiments utilizing mice were performed in accordance
with institutional and European guidelines (EU Directive 2010/63/EU) and were
approved by the local animal care and use committee (Comite Etico de Experi-
mentacion Animal at Universidad de Barcelona, protocol 135/11).
Pharmacokinetics. Nine-week-old female BALB/c mice were treated with LDN-
193189, LDN-213844, LDN-212838, LDN-214117, K05907 and saracatinib at
5 mg/kg drug intravenously, 5 mg/kg drug by oral gavage, or vehicle. 20 µl blood
was taken from the tail vein, spiked onto Whatman FTA DMPK-B cards and left to
dry for at least 6 h. Female NOD.SCID mice were similarly treated with either
35 mg/kg LDN-193189, 25 mg/kg LDN-214117 or vehicle orally, with 20 µl tail vein
blood taken at 1, 2, 4, 6 and 8 h after the ﬁrst dose and prepared as before. Plasma
and brain tissue samples were taken in triplicate at 2 h post-dose on day 14.
Analysis was carried out by liquid chromatography-tandem mass spectrometry
(LC-MS/MS) using a Waters Xevo TQS coupled with an Acquity UPLC H-class
system (Waters, Herts, UK). Chromatography was carried out using a Phenomenex
(Macclesﬁeld, UK) C18 X-B column (2.6 µm, 50 mm × 2.1 mm). Data acquisition
was performed using Targetlynx, version 4.1 and pharmacokinetic modelling was
carried out using Phoenix WinNonlin version 6.3 (Certara, NJ, USA).
In vivo efﬁcacy studies. A single cell suspension of each culture was made the day
before implantation and cultured overnight. On the implantation day, small
tumourspheres in exponential growth were harvested by mild centrifugation. 3-
week-old female NOD.SCID mice were anaesthetised with 100 mg/kg ketamine
and 10 mg/kg xylazine and immobilized in a stereotaxic apparatus (Stoelting,
Wood Dale, IL) at coordinates x+0.5 and y−5.4 from the bregma suture. 5 × 105
HSJD-DIPG-007 or HSJD-GBM-001 tumourspheres (5 × 105 cells), suspended in
5 μl matrigel (BD Biosciences) were injected at 3.1 mm depth (targeting the 4th
ventricle) with a dull 22G needle attached to a 50 μl syringe (Hamilton, Bonaduz,
Switzerland), using a stereotaxic arm. Mice were stratiﬁed (n= 7–10 per group)
and treated with 25 mg/kg of either LDN-193189, LDN-214117 or vehicle for
28 days, starting 21–28 days post-inoculation. LDN-193189 was prepared each day
in water whilst LDN-214117 was prepared in 10% DMSO diluted in saline. Mice
were monitored by daily weighing and were sacriﬁced by cervical dislocation upon
deterioration of condition or 20% weight loss from the maximum weight achieved,
with tissue taken for further analysis. Mouse brains collected at the end of the
efﬁcacy study were processed for immunohistochemistry. Plasma and brain sam-
ples from treated and control mice were taken at 2 h post-dose at the end of the 28-
day treatment for pharmacokinetic and pharmacodynamic analyses.
Immunohistochemistry. PFA-ﬁxed mouse brains were parafﬁn embedded and
sectioned (4 µm) for immunohistochemical analysis and stained with haematoxylin
and eosin (H&E). For immunohistochemistry, sodium citrate (pH 6.0) heat-
mediated antigen retrieval was performed and staining was carried out using an
antibody directed against human nuclear antigen (HNA) (Millipore, #4383, 1:100).
Pressure antigen retrieval was performed and staining was carried out using
antibodies directed against Ki67 (DAKO, #7240, 1:100), and CD31 (Abcam,
#28364, 1:50). All primary antibodies were diluted into 1% Tris buffer solution with
0.05% Tween-20, except Ki67 which was diluted into Dako antibody diluent.
Antibodies were incubated for 1 h at room temperature. Novocastra Novolink
Polymer Detection Systems Kit (Leica Biosystem RE-7150) was used for the
staining. Slides were then mounted using Leica CV Ultra mounting medium and
slides were imaged using the high throughput-scanning microscope AxioScan Z1.
Five ﬁelds of view were selected across sagittal and coronal cuts of the brain at 70%
zoom and images quantiﬁed using Image J and application Cell Counter44.
Statistics and reproducibility. Statistical analysis was carried out using R 3.3.0
(www.r-project.org) or GraphPad Prism version 6. Categorical comparisons of
counts were carried out using Fisher's exact test, comparisons between groups of
continuous variables employed Student’s t-test or ANOVA. Interventional in vitro
experiments were carried out with at least n= 3 biological replicates. Differences in
survival were analysed by the Kaplan–Meier method and signiﬁcance determined
by the log-rank test. All tests were two-sided and a p-value of less than 0.05 was
considered signiﬁcant. Multiple testing was accounted for using false discovery rate
q-values or the Bonferroni adjustment.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The bioinformatic datasets generated analysed during the current study are available in
the paediatric-speciﬁc implementation of the cBioPortal genomic data visualisation
portal (http://www.pedcbioportal.org). Data showing gene expression differences in
ACVR1 mutant vs wild-type 3 DIPG samples can be found on Supplementary Data 1.
The authors declare that all other data supporting the ﬁndings of this study are available
within the article, Supplementary Information ﬁles or available from the authors upon
reasonable request.
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